References



- **Abdalla S, Lother H, Langer A, et al. (2004):** Factor XIIIA transglutaminase crosslinks AT₁ receptor dimmers of monocytes at the onset of atherosclerosis. Cell; 119: 343-354.
- **Abramson JL, Jurkovitz CT, Vaccarino V, et al. (2003):** Chronic kidney disease, anemia, and incident stroke in a middle-aged,community-based population: The ARIC study. Kidney Int; 64: 610-615.
- **Albers GW, Caplan LR, Easton JD, et al. (2002):** Transient ischemic attack: Proposal for a new definition. N Engl J Med; 347: 1713-1716.
- Amarenco P, Bogousslavsky J, Callahan AS, et al. (2003): Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovascular diseases 16 (4): 389–95.
- Anavekar NS, McMurray JJV, Velazquez EJ, (2004): Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. N Engl J Med; 351: 1285-1295.
- Annuk M, Lind L, Linde T and Fellstrom B (2001): Impaired endothelium dependent vasodilatation in renal failure in humans. Nephrol Dial Transplant; 16: 302-306.
- Austen SK, Coombes JS and Fassett RG (2003): Homocysteine and cardiovascular disease in renal disease. Nephrology; 8: 285-295.
- **Ayabe N, et al. (2006):** Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. Atherosclerosis; 184: 312-321.

References 9.

B


Babaev, V. R. et al. (2000): Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell. Metab. 8, 492–501.

- **Baker WL, et al. (2009):** Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann. Intern. Med.; 151: 861-871.
- Barter PJ, Caulfield M, Eriksson M, et al. (2007): Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 357 (21): 2109–22.
- Bash, L.D.; Erlinger, T.P. and Coresh, J. et al. (2009): Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk In Communities (ARIC) Study. Am J Kidney Dis; 53(4): 596-605.
- **Becker L, et al. (2010):** A macrophage sterol-responsive network linked to atherogenesis. Cell. Metab.; 11: 125-135.
- Berg Ak, Duval S and Krumholz HM (2003): Aspirin beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol; 42: 201-208.
- **Blankestijn PJ** (2004): Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant; 19: 1354-1357.
- **Blessing E, et al. (2008):** Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis; 199: 295-303.

Bohlender JM, Frnake S, Stein G, et al. (2005): Advanced glycation endproducts and the kidneys. Am. J. Physiol. Renal Physiol.; 289: F645-F659.

- **Böhm F, Settergren M, Pernow J (2007):** Vitamin C blocks vascular dysfunction and release of interleukin-6 induced by endothelin-1 in humans in vivo. Atherosclerosis 190 (2): 408–15.
- Bolton CH, Downs LG, Victory JGG, et al. (2001): Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and proinflammatory cytokines. Nephrol Dial Transplant; 16: 1189- 1197
- **Brewer GJ (2007):** Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Exp. Biol. Med. (Maywood) 232 (2): 323–35.
- **Bro, S.** (2009): Cardiovascular effects of uremia in apolipoprotein E-deficient mice. Dan. Med. Bull. 56, 177–192.
- **Bro, S. et al. (2003):** Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J. Am. Soc. Nephrol. 14, 2466–2474.
- **Bro, S., Moeller, F., Andersen, C. B., et al. (2004):** Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice. J. Am. Soc. Nephrol. 15, 1495–1503.

References 9 Y



Campean, V. et al. (2007): CD40–CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure. Atherosclerosis 190, 156–166.

- Caplan LR, Wityk RJ, Glass TA, et al. (2004): New England Medical Center Posterior Circulation Registry. Ann Neurol; 56: 389-398.
- Cardinal H, Raymond MA, Hebert MJ, et al. (2007): Uraemic plasma decreases the expression of ABCA₁, ABCG₁ and cell-cycle genes in human coronary arterial endothelial cells. Nephrol. Dial. Transplant.; 22: 409-416.
- Chamorro A, Sacco RL, Mohr JP, et al. (1991): Clinical-computed tomographic correlations of lacunar infarction in the Stroke Data Bank. Stroke; 22: 175-181.
- Chen J, Muntner P, Hamm LL, et al. (2003): Insulin Resistance and Risk of Chronic Kidney Disease in Nondiabetic US Adults. J Am Soc Nephrol; 14: 469-477.
- Chen M, Li W, Wang N, et al. (2007): ROS and NK-κB but not LXR mediate IL-1β signaling for the downregulation of ATP-binding cassette transporter A₁. Am. J. Physiol. Cell. Physiol.; 292: C1493-C1501.

References 9T

Cheng J, Ke Q, Jin Z, et al. (2009): Cytomegalovirus Infection Causes an Increase of Arterial Blood Pressure. PLoS Pathog 5 (5): e1000427.

- Chmielewski, M. et al. (2005): Expression of scavenger receptor CD36 in chronic renal failure patients. Artif. Organs 29, 608–614.
- Conneally PM, Dyken ML, Futty DE, et al. (1978): Cooperative study of hospital frequency and character of transient ischemic attacks. VIII. Risk factors. JAMA; 240: 742-746.
- Cuchel, M. and Rader, D. J. (2006): Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 113, 2548–2555.
- Culleton BF, Larson MG, Wilson PWF, et al. (1999): Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int; 56: 2214-2219.



Dahlof B, Devereux RB, Kjeldsen SE, et al. (2002):

Cardiovascular morbidity and mortality in the Losartan

Intervention For Endpoint reduction in hypertension study

(LIFE): A randomized trial against atenolol. Lancet; 359: 995
1003.

de Leeuw PW, Ruilope LM, Palmer CR, et al. (2004): Clinical Significance of Renal Function in Hypertensive Patients at High Risk. Arch Intern Med; 164: 2459-2464.


- **DeFrances CJ and Hall MJ (2005):** National hospital discharge survey. Adv Data; 385: 1-19.
- Denke MA and Grundy SM (1996):

 Dyslipoproteinemias/atherosclerosis: Dietary therapy. In: Smith
 T, ed. Cardiovascular therapeutics. Philadelphia, WB Saunders;
 385-402.
- Diaz MN, Frei B and Vita JA (1997): Antioxidants and atherosclerotic heart disease. N Engl J Med.
- **Didangelos A, Simper D, Monaco C, et al. (2009):** Proteomics of acute coronary syndromes. Current atherosclerosis reports 11 (3): 188–95.
- **Diener HC, Bogousslvsky J, Brass LM, et al. (2004):** Aspirin and clipidogrel versus clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): Randomized, double-blind, placebo-controlled trial. Lancet; 364: 331-337.
- **Diener HC, Cunha L, Forbes C, et al. (1996):** European stroke prevention study: II. Dipyridamole and acetylsalicyclic acid in the secondary prevention of stroke. J Neurol Sci; 143: 1-13.
- **Dobarganes C, Márquez-Ruiz G (2003):** Oxidized fats in foods. Curr Opin Clin Nutr Metab Care; 6(2): 157-63.



Ejerblad E and Fored CM (2004): Association between smoking and chronic renal failure in a nationwide population-based casecontrol study. J Am Soc Nephrol; 15: 2178-2185.

- **Erbay, E. et al. (2009):** Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat. Med. 15, 1383–1391.
- Erkkilä AT, Booth SL (2008): Vitamin K intake and atherosclerosis. Curr. Opin. Lipidol. 19 (1): 39–42.
- Ethier J, Bragg-Gresham JL, Piera L, et al. (2007): Aspirin perscription and outcomes in hemdialysis patients: The DIalysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney DIs; 50: 602-611.
- Evenson KR, Rosamond WD and Morris DL (2001): Prehospital and in-hospital delays in acute stroke care. Neuroepidemiology; 20: 65-76.



Finn AV, Nakano M, Narula J, et al. (2010): Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol; 30(7):1282-92.

Foley RN, Parfrey PS and Sarnak MJ (1998): Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis; 32: S112-S119.

Fukuda D, Sata M, Ishizaka N, et al. (2007): Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice. Arterioscler. Thromb. Vasc. Biol.; 28: 90-96.



- Garg AX, Blake PG, Clark WF, et al. (2001): Association between renal insufficiency and malnutrition in older adults: Results from the NHANES III. Kidney Int; 60: 1867-1874.
- Garg AX, Clark WF, Haynes RB, et al. (2002): Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney International; 61: 1486-1494.
- Gent M, Blakely JA, Easton JD, et al. (1989): The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet; 1: 1215-1220.
- Gerraty RP, Parsons MW, Barber PA, et al. (2002): Examining the lacunar hypothesis with diffusion and perfusion magnetic resonance imaging. Stroke; 33: 2019-2024.
- **Ginter E (2007):** Chronic vitamin C deficiency increases the risk of cardiovascular diseases. Bratisl Lek Listy 108 (9): 417–21.

Glagov S, Weisenberg E, Zarins CK, et al. (1987): Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 316 (22): 1371–5.y

- Glass, C. K. and Witztum, J. L. (2001): Atherosclerosis: the road ahead. Cell 104, 503–516.
- Go AS, Chertow GM, Fan D, et al. (2004): Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med; 351: 1296–1305.
- Gollapudi P, Yoon JW, Gollapudi S, et al. (2010): Leukocyte toll-like receptor expression in end-stage kidney disease. Am. J. Nephrol.; 31: 247-254.
- **Goodman WG (2004):** The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Seminars in Dial; 17: 209-216.
- **Goodman WG and London G (2004):** Vascular Calcification in Chronic Kidney Disease. Am J Kidney Dis; 43 (3): 572-579.
- Gorelick P and Weisman S (2005): Risk of hemorrhagic stroke with aspirin use: An update. Stroke; 36: 1801-1807.
- **Grahl DA, et al. (2007):** Associations between the CYBA 242C/T and the MPO-463G/A polmorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients. Blood Purif; 25: 210-218.

References 9A

Greco AV, Mingrone G (1990): Serum and biliary lipid pattern in rabbits feeding a diet enriched with unsaturated fatty acids. Exp Pathol 40 (1): 19–33. PMID 2279534.

- **Gruppo IPL** (1999): Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-prevention trial. Lancet; 354(9177): 447-55.
- Gugliucci A, et al. (2007): Acrolein inactivates paraoxonase-1: Changes in free acrolein levels after hemodialysis correlate diwth increases in paraoxonase-1 activity in chronic renal failure patients. Clin. Chim. Acta; 384: 105-112.




- **Harb D, et al. (2009):** The role of the scavenger receptor CD₃₆ in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation. Cardiovasc. Res.; 83: 42-51.
- Harwood HG, Greene YJ and Stacpoole PW (1986): Inhibition of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by ascorbic acid. An effect mediated by the free radical monodehydroascorbate. J. Biol. Chem. 261 (16): 7127–7135.
- Hennekens CH, Buring JE, Sandercock P, et al. (1989): Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation; 80: 749-756.

Henry RMA, Kostense PJ, Bos G, et al. (2002): Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int; 62: 1402-1407.

- Herzig KH, Purdie DM, Chang W, et al. (2001): Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol; 12: 814-821.
- **Hiro T, Fuji T and Yoshitake S (2000):** Longitudinal visualization of spontaneous coronary plaque rupture by 3D intravascular ultrasound. Circulation; 101(12): E114-5.
- **Huo, Y. and Ley, K. (2001):** Adhesion molecules and atherogenesis. Acta Physiol. Scand. 173, 35–43.



- **Ibañez B, Badimon JJ, Garcia MJ (2009):** Diagnosis of Atherosclerosis by Imaging. Am J Med.; 122(1): S15-S25.
- **Ishani A, Herzog CA and Collins AJ (2004):** Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Kidney Int; 65: 1017-1025.



Kaufman JS, O'Connor TZ, Zhang JH, et al. (2003): Randomized controlled trial of clipidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol; 14: 2313-2321.

- Kawamura M, Fijimoto S, Hisanaga S, et al. (1998): Incidence, Outcome, and Risk Factors of Cerebrovascular Events in Patients Undergoing Maintenance Hemodialysis. Am J Kidney Dis; 31: 991-996.
- **Kaysen, G. A. and Eiserich, J. P. (2004):** The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J. Am. Soc. Nephrol. 15, 538–548.
- **Kelly J, Hunt BJ, Ruddet A, et al. (2002):** Should patients with lacunar stroke and severe carotid artery stenosis undergo endarterectomy? Q J Med; 95: 313-319.
- **Kennedy R, Case C, Fathi R, et al. (2001):** Does renal failure cause an atherosclerotic milieu in patients with end- stage renal disease? Am J Med; 110: 198-204.
- Khandanpous N, Loke YK, Meyer FJ, et al. (2009): Homocysteine and peripheral arterial disease: Systematic review and meta-analysis. Eur J Vasc Endovasc Surg.

Kielstein JT, Bode-Boger, Frolich JC, et al. (2001): Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int; Suppl 78: S9-13.

- Kielstein JT, Boger RH, Bode-Boger SM, et al. (2002): Marked Increase of Asymmetric Dimethylarginine in Patients with Incipient Primary Chronic Renal Disease. J Am Soc Nephrol; 13: 170-176.
- **Kim HJ, Moradi H, Yuan J, et al. (2009):** Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am. J. Physiol. Renal Physiol.; 296: F1297-F1306.
- King, Cr; Knutson, Kl; Rathouz, Pj; et al. (2008): Short sleep duration and incident coronary artery calcification.. JAMA: the journal of the American Medical Association 300 (24): 2859–66.
- **Kohlhagen J and Kelly J (2003):** Prevalence of vascular risk factors and vascular disease in predialysis chronic renal failure. Nephrology; 8: 274-279.
- Kronmal RA, Hart RG, Manolio TA, et al. (1998): Aspirin use and incident stroke in cardiovascular health study. Stroke; 29: 887-894.
- **Kuroki Y, et al. (2007):** A study of innate immunity in patients with end-stage renal disease: Special reference to toll-like receptor-2 and -4 expression in peripheral blood monocytes of hemodialysis patients. Int. J. Mol. Med.; 19: 783-790.



Levey AS, et al. (2003): National kidney foundation practice guidelines for CKD evaluation: Classification and stratification. Annals of Internal Medicine; 139(2): 137-147.

- Levine GN, Keaney JF Jr and Vita JA (1995): Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms. N ENgl J Med; 332(8): S12-21.
- **Levy D** (1988): How transient are transient ischemic attacks? Neurology; 38: 674-677.
- **Libby P (2000):** Changing concepts of atherogenesis. J Intern Med; 247(3): 349-58.
- **Liu J and ROsner MH (2006):** Lipid abnormalities associated with end-stage renal disease. Semin. Dial.; 19: 32-40.
- Liu Y, Coresh J, Eustace JA, et al. (2004): Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA; 291: 451-459.
- **Lodder J, Bamford JM, Sandercock PA, et al. (1990):** Are hypertension or cardiac embolism likely causes of lacunar infarction. Stroke; 21: 375-381.
- **London GM, Blache J, Pannier B, et al. (2001):** Arterial Wave Reflections and Survival in End-Stage Renal Failure. Hypertension; 38: 434-438.



Malouf R and Grimley Evans J (2008): Folic acid with or without vitamin B12 for the prevention and treatment of elderly and people with atherosclerosis. Cochrane Database Syst Rev.; CD004514.

- Manjunath G, Tighiouart H, Coresh J, et al. (2003): Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int; 63: 1121-1129.
- Mann JFE, Gerstein HC, Pogue J, et al. (2001): Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial. Ann Intern Med; 134: 629-636.
- Mann, J. F., Gerstein, H. C., Pogue, J., et al. (2001): Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 134, 629–636.
- **Marleau S, et al. (2005):** EP-90317, a ligand of the CD₃₆ scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J; 19: 1869-1871.
- Maschio S, et al. (1996): Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med.; 334: 939-945.

Maseri A, Fuster V (2003): Is there a vulnerable plaque?. Circulation 107 (16): 2068–71.

- Maton A, Jean Hopkins RL, McLaughlin CW, et al. (2003): Human biology and health. Englewood Cliffs, New Jersey, USA: Prentice Hall.
- **Mattes RD** (2005): Fat taste and lipid metabolism in humans. Physiol. Behav. 86 (5): 691–7.
- McClellan W, Aronoff SL, Bolton WK, et al. (2004): The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin; 20: 1501–1510.
- McDonald S and Russ G (editors) (2003): ANZDATA Registry Report. Australian and New Zealand Transplant Registry. Adelaide, South Australia.
- McMahon LP, Roger SD and Levin A (2004): Development, Prevention, and Potential reversal of Left Ventricular Hypertrophy in Chronic Kidney Disease. J Am Soc Nephrol; 15: 1640-1647.
- Messé SR, Silverman JE, Kizer JR, et al. (2004): Practice parameter: Recurernt stroke with patent foramen ovale and atrial septal aneurysm: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology; 62: 1042-1050.

Michelsen, K. S. et al. (2004): Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl Acad. Sci. USA 101, 10679–10684.


- Mitchell RS, Kumar V, Abbas AK, et al. (2007): Robbins Basic Pathology. Philadelphia: Saunders; 345.
- Miyagi, M. et al. (2010): Impact of renal function on coronary plaque composition. Nephrol. Dial. Transplant. 25, 175–181.
- Mohr J (1986): Lacunar stroke. Hypertension; 8: 349-356.
- Montecucco F, Pende A and Mach F (2009): The renninangiotensin system modulates inflammatory processes in atherosclerosis: Evidence from basic research and clinical studies. Mediators Inflamm.
- Moradi H, Yuan J, Ni Z, et al. (2009): Reverse cholesterol transport pathway in experimental chronic renal failure. Am. J. Nephrol.; 30: 147-154.
- Mullan BA; Young IS; Fee H; et al. (2002): Ascorbic Acid Reduces Blood Pressure and Arterial Stiffness in Type 2 Diabetes. Hypertension 40 (6): 804–9.



Nagao T, Qin C, Grosheva I, et al. (2007): Elevated cholesterol levels in the plasma membranes of macrophages inhibit migration by disrupting RhoA regulation. Arterioscler. Thromb. Vasc. Biol.; 27: 1596-1602.

Nakayaraa M, Metoki H, Terawaki H, et al. (2007): Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population: The Ohasama study. Nephrol Dial Transplant; 22: 19190-1915.

- Nanayakkara, P. W. et al. (2009): Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. Am. J. Kidney Dis. 53, 41–50.
- Narain VS, Gupta N, Sethi R, et al. (2008): Clinical correlation of multiple biomarkers for risk assessment in patients with acute coronary syndrome. Indian Heart J; 60(6):536-42.
- **Nissen SE, Nicholls SJ, Sipahi I, et al. (2006):** Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (13): 1556–65.



O'Hare AM, Vittinghoff E, Hsia J and Shlipak MG (2004):
Renal Insufficiency and the Risk of Lower Extremity Peripheral
Arterial Disease: Results from the Heart and Estrogen/Progestin
Replacement Study (HERS). J Am Soc Nephrol; 15: 10461051.

Oberg BP, McMenamin E, Lucas EL, et al. (2004): Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int; 65: 1009-1016.

- **Osada, S. et al. (2009):** Alterations in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patients. Nephrol. Dial. Transplant. 24, 3504–3512.
- Ovbiagele B, Kidwell C and Saver J (2003): Epidemiological impact in the United States of a tissue-based definition of transient ischemic attack. Stroke; 34: 919-924.
- Overton, C. D., Yancey, P. G., et al. (2007): Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse. Circ. Res. 100, 670–677.



- Pahl, M. V., Vaziri, N. D., Yuan, J. et al. (2010): Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 5, 56–61.
- Pai JK, Pischon T, Ma J, et al. (2004): Inflammatory Markers and the Risk of Coronary Heart Disease in Men and Women. N Engl J Med; 351: 2599-2610.

References 1.A

Park, Y. M., Febbraio, M. and Silverstein, R. L. (2009): CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J. Clin. Invest. 119, 136–145.

- **Pedersen TX, et al. (2009):** Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient mice. Atherosclerosis; 202: 372-381.
- Pencina MJ, D'Agostino RB Sr, Larson MG, et al. (2009): Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation; 119(24): 3078-84.
- Pereira AA, Weiner DE, Scott T, et al. (2007): Subcorticalcognitive impairment in dialysis patietns. Hemodial Int; 11: 309-314.
- **Peters, W. and Charo, I. F. (2001):** Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr. Opin. Lipidol. 12, 175–180.
- **Peto R, Gray R, Collins K, et al. (1988):** Randomized trial of prophylactic daily aspirin in British male doctors. BMJ; 296: 313-316.
- **Pinderski, L. J. et al. (2002):** Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ. Res. 90, 1064–1071.

Podrez EA, et al. (2000): Macrophage scavenger receptor CD₃₆ is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest.; 105: 1095-1108.

- **Prichard SS (2003):** Impact of Dyslipidemia in End-Stage Renal Disease. J Am Soc Nephrol; 14: S315-S320.
- Prinsen E, Rabelink TJ, Beutler JJ, et al. (2003): Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. Kidney Int; 64: 1495-1504.



Qiu G and Hill JS (2008): Atorvastatin inhibits ABCA₁ expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J. Cardiovasc. Pharmacol.; 51: 388-395.



- Rath M and Pauling L (1992): A unified theory of human cardiovascular disease leading the way to the abolition of this disease as a cause for human mortality. Journal of Orthomolecular Medicine 7 (1): 5–15.
- **Rigatto, C. et al. (2009):** Atheroma progression in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 291–298.
- **Rinkel GJ (2005):** Intracranial aneurysm screening: Indications and advice for practice. Lancet Neurol; 4: 122-128.

Robert T, Alessandro R. Dodesini, et al. (2008): Lipids and renal disease. J Am Soc Nephrol; 17: s145-s147.

- Rosamond W, Flegal K, Furie K, et al. (2008): Heart disease and stroke statistics. Update: A report from the American Heart Association Statistics Committee and Stroke Statistics subcommittee. Circulation; 117: e25-146.
- **Ross R and Ross R (1999):** Atherosclerosis: An Inflammatory Disease. New England Journal of Medicine 340 (2): 115–26.
- Rothwell PM, Eliasziw M, Gutnikov SA, et al. (2003): Carotid endarterectomy trialists' collaboration: Analysis of pooled data from the randomized controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet; 361: 107-116.
- Ruggenenti P, Perna A, Gherardi G, et al. (1998): Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet; 352: 1252-1256.
- Ruilope LM, Salvetti A, Jamerson K, et al. (2001): Renal Function and Intensive Lowering of Blood Pressure in Hypertensive Participants of the Hypertension Optimal Treatment (HOT) Study. J Am Soc Nephrol; 12: 218-225.



Sales VL, et al. (2005): Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. Circulation; 112: 3328-3336.

- **Sasaki T, et al. (2010):** AT₁ blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice. Atherosclerosis; 210: 430-437.
- **Sato K, Dohi Y, Kojima M, et al. (2006):** Effects of ascorbic acid on ambulatory blood pressure in elderly patients with refractory hypertension. Arzneimittelforschung 56 (7): 535–40.
- **Savage T, Clarke AL, Giles M, et al.** (2004): Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease. Nephrol Dial Transplant; 13: 1998-2012.
- Sela, S. et al. (2005): Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J. Am. Soc. Nephrol. 16, 2431–2438.
- Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, et al. (2003): Elevated risk of stroke among patients with end-stage renal disease. Kidney Int; 64: 603-609.
- **Selwyn AP, Kinlay S and Libby P (2007):** Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation; 95(1): 5-7.

Sesso, H. D. et al. (2008): Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 300, 2123–2133.

- Sever PS, Poulter NR, Dahlöf B, et al. (2005): Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm (ASCOT-LLA). Diabetes Care 28 (5): 1151–7.
- Shinohara K, Shoji T, Emoto M, et al. (2002): Insulin Resistance as an Independent Predictor of Cardiovascular Mortality in Patients with End-Stage Renal Disease. J Am Soc Nephrol; 13: 1894-1900.
- Shlipak MG, Fried LF, Crump C, et al. (2003): Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency. Circulation; 107: 87-92.
- Shoji T, Emoto M, Shinohara K, et al. (2001): Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol; 12: 2117-2124.
- **Sigrist M, Bungay P, Taal MW, et al. (2006):** Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant; 21: 707-714.
- **Song JH, Fujimoto K, Miyazawa T (2000:** Polyunsaturated (n-3) fatty acids susceptible to peroxidation are increased in plasma and tissue lipids of rats fed docosahexaenoic acid-containing oils. J. Nutr. 130 (12): 3028–33.
- **Sozio SM, Armstrong PA, Coresh J, et al. (2009):** Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: The Choices for Healthy Outcomes In Caring for ESRD (CHOICE) study. Am J Kidney Dis; 54: 68-477.

Steering Committee of the Physicians' Health Study Research Group (1989): Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med; 321: 129-135.

- Stenvinkel P, Heimburger O, Lindholm B, et al. (2000): Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant; 15: 953-960.
- **Stenvinkel P, Heimburger O, Paultre F, et al. (1999):** Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int; 55: 1899-1911.
- **Stinghen, A. E. et al. (2009):** Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin. Pract. 111, c117–c126.
- Strandberg, TE, Lehto S, Pyörälä K, et al. (1997): Cholesterol lowering after participation in the Scandinavian Simvastatin Survival Study (4S) in Finland. European Heart Journal 18 (11): 1725–1727.
- Suganuma, E. et al. (2006): Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. J. Am. Soc. Nephrol. 17, 433–441.
- **Sullivan JL and Mascitelli L (2007):** Current status of the iron hypothesis of cardiovascular diseases. Recenti Prog Med 98 (7-8): 373–7.



Tabas, I. (2005): Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 25, 2255–2264.

- **Tabas, I.** (2010): Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36–46.
- **Takaya T, et al. (2006):** Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis; 186: 402-410.
- **Tang C, Kanter JE, Bornfeldt KE, et al. (2010):** Diabetes reduces the cholesterol exporter ABCA₁ in mouse macrophages and kidneys. J. Lipid Res.; 51: 1719-1728.
- **Tarakji A, McConaughy A, Nicholas G (2006):** The risk of carotid endaraterectomy in patients with chronic renal insufficiency. J Vasc Surg; 63: 326-329.
- **Taubes G (2001):** Nutrition. The soft science of dietary fat. Science 291 (5513): 2536–45.
- **Tepel, M., van der Giet, M., Statz, M., et al. (2003):** The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107, 992–995.

Thom T, Haase N, Rosamond W, et al. (2006): American Heart Association statistics committee and stroke statistics subcommittee: Heart disease and stroke statistics: Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation; 113: e85-e151.

- **Tonelli M, Moye L, Sacks FM, et al. (2003):** Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med; 138: 98-104.
- **Toyoda K, Fujii K, Fujimi S, et al.** (2005): Stroke in patients on maintenance hemodialysi: A 22-year single-center study. Am J Kidney Dis; 45: 1058-1066.
- **Toyoda K, Fujii K, Fujimi S, et al. (2005):** Stroke in patients on maintenance hemodialysis: A 22-year single-center study. Am J Kidney Dis; 45: 1058-1066.
- Trespalacios FC, Taylor AJ, Agodoa LY and Abbott KC (2002): Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int; 62: 1799-1805.
- **Trogan, E. et al. (2006):** Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc. Natl Acad. Sci. USA 103, 3781–3786.
- Tsimihodimos V, Dounousi E and Siamopoulos KC (2008): Dyslipidemia in chronic kidney disease: An approach to pathoenesis and treatment. Am. J. Nephrol.; 28: 958-973.
- **Tsubakimoto Y, et al. (2009):** Bone marrow angiotensin AT₁ receptor regulates differentiation of monocyte lineage progenitors from hematopoietic stem cells. Arterioscler. Thromb. Vasc. Biol.; 29: 1529-1536.



Uehata A, Liberman EH and Gehard MD (1997): Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med; 2(2): 87-92.

- **Ueland PM, Refsum H, Beresford SA, et al. (2000):** The controversy over homocysteine and cardiovascular risk. Am J Clin. Nutr; 72: 324 332.
- Usberti M, Gerardi GM, Gazzotti RM, et al. (2002): Oxidative Stress and Cardiovascular Disease in Dialyzed Patients. Nephron; 91: 25-33.
- USRDS "U.S. Renal Data System" (2003) Annual Data Report:

 Atlas of End-Stage Renal Disease in the United States, National
 Institutes of Health, National Institute of Diabetes and Digestive and
 Kidney Diseases, Bethesda, MD, 2003.



- Vaziri ND, Gonzales EC, Wang J, et al. (1994): Blood Coagulation, Fibrinolytic, and Inhibitory Proteins in End-stage Renal Disease: Effect of Hemodialysis. Am J Kidney Dis; 23: 828-835.
- Vaziri ND, Moradi H, Pahl MV, et al. (2009): In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an ApoA-1 mimetic peptide. Kidney Int; 76: 437-444.



Wald NJ and Law MR (2003): A strategy to reduce cardiovascular disease by more than 80%. BMJ (Clinical research ed.) 326 (7404): 1419.

- Wallin R, Schurgers L, Wajih N (2008): Effects of the blood coagulation vitamin K as an inhibitor of arterial calcification. Thromb. Res. 122 (3): 411–7.
- Wang J, Staessen JA, Fagard RH, et al. (2001): Prognostic Significance of Serum Creatinine and Uric Acid in Older Chinese Patients With Isolated Systolic Hypertension. Hypertension; 37: 1069-1074.
- Wang, Z. et al. (2007): Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 13, 1176–1184.
- Wannamethee SG, Shaper AG and Perry IJ (1997): Serum Creatinine Concentration and Risk of Cardiovascular Disease: A Possible Marker for Increased Risk of Stroke. Stroke; 28(3): 557-563.
- Wanner C and Krane V (2003): Non-High-Density Lipoprotein Cholesterol: A Target of Lipid-Lowering in Dialysis Patients. Am J Kidney Dis: 41, Suppl 1; S72-S75.

Wanner C, Krane V, Marz W, et al. (2005): Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med; 353: 238-248.

- Webe MA, Julius S, Kjeldsen SE, et al. (2004): Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet; 363: 2049-2051.
- Weiner DE, Tighiouart H, Amin MG, et al. (2004): Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of communitybased studies. J Am Soc Nephrol; 15: 1307-1315.
- Weiner DE, Tighiouart H, Levey AS, et al. (2007): Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol; 18: 960-966.
- Weinstock Brown W and Keane WF (2001): Proteinuria and Cardiovascular Disease. Am J Kidney Dis; 38, suppl 1: S8-13.
- Wheeler DC, Townend JN and Landray MJ (2003): Cardiovascular risk factors in predialysis patients: Baseline data from the Chronic Renal Impairment in Birmingham (CRIB) Study. Kidney Int; 63 (suppl 84): S201-203.
- Wong J, Quinn CM, Gelissen IC, et al. (2008): The effect of statins on ABCA₁ and ABCG₁ expression in human macropohages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis; 196: 180-189.



Yancey, P. G. et al. (2003): Importance of different pathways of cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 23, 712–719.

- **Yancey, P. G. et al. (2010):** Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. Arterioscler. Thromb. Vasc. Biol. 30, 787–795.
- Yancey, P. G., Yu, H., Linton, M. F. et al. (2007): A pathway-dependent on ApoE, ApoA₁, and ABCA₁ determines formation of buoyant high-density lipoprotein by macrophage foam cells. Arterioscler. Thromb. Vasc. Biol. 27, 1123–1131.
- Yap SC, Choo YM, Hew NF, et al. (1995): Oxidative susceptibility of low density lipoprotein from rabbits fed atherogenic diets containing coconut, palm, or soybean oils. Lipids 30 (12): 1145–50. doi:10.1007/BF02536616. PMID 8614305.
- Yoon, J. W., Pahl, M. V. and Vaziri, N. D. (2007): Spontaneous leukocyte activation and oxygen-free radical generation in endstage renal disease. Kidney Int. 71, 167–172.
- **Yvan-Charvet L, Wang N and Tall AR (2010):** Role of HDL, ABCA₁, and ABCG₁ transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol.; 30: 13-143.

References 17.



Zacharski LR, Chow BK, Howes PS, et al. (2007): Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 297 (6): 603–10.

- **Zhu X, et al. (2008):** Increased cellular free cholesterol in macrophage-specific Abca₁ knock-out mice enhances proinflammatory response of macrophages. J. Biol. Chem.; 283: 22930-22941.
- **Zoungas Z, Branley P, Kerr PG, et al. (2004):** The Atherosclerosis and Folic Acid Supplementation Trial in Chronic Renal Failure (ASFAST): Baseline Results. Nephrol; 9: 130-141.
- **Zuo Y, et al. (2009):** Renal dysfunction potentiates foam cell formation by repressing ABCA₁. Arterioscler. Thromb. Vasc. Biol.; 29: 1277-1282.